Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.31 |
| ▸ | WRN | Q14191 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 3/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | P4HB | P07237 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077467 | 0.87 | OPRM1 (0.34) | — | |
| SCHEMBL7081436 | 0.86 | MTNR1B (0.32) | MTNR1B | |
| SCHEMBL6295657 | 0.85 | ESR1 (0.35) | — | |
| SCHEMBL6295928 | 0.85 | ESRRG (0.32) | — | |
| SCHEMBL7077373 | 0.84 | LMNA (0.33) | — | |
| SCHEMBL6295957 | 0.84 | ESR1 (0.36) | WRNBCHE | |
| SCHEMBL7143558 | 0.83 | MTNR1A (0.37) | MTNR1AMTNR1BCYP2D6BCHE | |
| SCHEMBL7080698 | 0.82 | ESRRG (0.35) | P4HB | |
| SCHEMBL7077370 | 0.82 | OPRM1 (0.34) | — | |
| SCHEMBL7078827 | 0.78 | DRD2 (0.34) | BCHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | claimed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | DNPEP, PRSS1, PREP | MTNR1A 4748/4885MTNR1B 4693/4885SLC13A5 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.